Cancer is a challenging therapeutic target. Cancer cells rapidly mutate, often metastasizing throughout the body. Because of these characteristics, therapies based on a single target or biological pathway typically have a limited efficacy window. Further, the twenty-eight (28) solid tumor cancer therapies approved by the FDA in the last five (5) years have an average survival extension of only 5.4 months. Meanwhile, the high toxicity of most cancer therapies typically results in a poor quality of life for patients.
NED’s combination therapies are designed to attack cancer on multiple fronts simultaneously. NED’s combinations utilize a dosing approach of the individual components at sub-toxic levels. We believe multi-component therapies will transform advanced cancer (stages II-IV) into a chronic, manageable disease.
We are developing NED-170, our lead therapeutic candidate, to be a first-in-class combination therapy. It is designed to simultaneously attack four key processes of all advanced solid tumor cancers using a well-tolerated, oral dosing regimen. We have observed the potential benefit and tolerability of the therapy in 27 patients. NED-170 holds promise not just to change long-term outcomes in numerous cancers, but to radically improve the patient experience during treatment.